Methylation Data Processing Protocol and Comparison of Blood and Cerebral Spinal Fluid Following Aneurysmal Subarachnoid Hemorrhage

Annie I. Arockiaraj1, Dongjing Liu1, John R. Shaffer1,2, Theresa A. Koleck3, Elizabeth A. Crago4, Daniel E. Weeks1,5 and Yvette P. Conley1,4*

1 Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States, 2 Center for Craniofacial and Dental Genetics, Department of Oral Biology, School of Dental Medicine, University of Pittsburgh, Pittsburgh, PA, United States, 3 School of Nursing, Columbia University, New York, NY, United States, 4 School of Nursing, University of Pittsburgh, Pittsburgh, PA, United States, 5 Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, United States

One challenge in conducting DNA methylation-based epigenome-wide association study (EWAS) is the appropriate cleaning and quality-checking of data to minimize biases and experimental artifacts, while simultaneously retaining potential biological signals. These issues are compounded in studies that include multiple tissue types, and/or tissues for which reference data are unavailable to assist in adjusting for cell-type mixture, for example cerebral spinal fluid (CSF). For our study that evaluated blood and CSF taken from aneurysmal subarachnoid hemorrhage (aSAH) patients, we developed a protocol to clean and quality-check genome-wide methylation levels and compared the methylomic profiles of the two tissues to determine whether blood is a suitable surrogate for CSF. CSF samples were collected from 279 aSAH patients longitudinally during the first 14 days of hospitalization, and a subset of 88 of these patients also provided blood samples within the first 2 days. Quality control (QC) procedures included identification and exclusion of poor performing samples and low-quality probes, functional normalization, and correction for cell-type heterogeneity via surrogate variable analysis (SVA). Significant differences in rates of poor sample performance was observed between blood (1.1% failing QC) and CSF (9.12% failing QC; p = 0.003). Functional normalization increased the concordance of methylation values among technical replicates in both CSF and blood. SVA improved the asymptotic behavior of the test of association in a simulated EWAS under the null hypothesis. To determine the suitability of blood as a surrogate for CSF, we calculated the correlations of adjusted methylation values at each CpG between blood and CSF globally and by genomic regions. Overall, mean within-CpG correlation was low (r < 0.26), suggesting that blood is not a suitable surrogate for global methylation in CSF. However, differences in the magnitude of the correlation were observed by genomic region (CpG island, shore,
INTRODUCTION

The epigenome-wide association study (EWAS) approach has emerged in recent years as a hypothesis-free method for investigating the associations between epigenetic marks, such as DNA methylation, and human phenotypes. Challenges pertaining to the cleaning and processing of methylomic data persist, including issues related to sample quality, controlling for cell type heterogeneity, comparing methylomic profiles across tissue types, and modeling dynamic changes in methylation over time (Morris and Beck, 2015). Here, we describe our quality control (QC) pipeline for processing and quality-checking genome-wide methylation data obtained from samples of blood and cerebral spinal fluid (CSF) in a cohort of acute subarachnoid hemorrhage (aSAH) patients. aSAH is a form of stroke leading to variation in clinical outcomes such as cerebral vasospasm, coma, delayed cerebral ischemia (DCI), cognitive decline, and death (Wermer et al., 2007). Previous work (Endres et al., 2000; Nelson et al., 2008; Stapels et al., 2010) has suggested that changes in DNA methylation occur following aSAH. We hypothesize that these methylomic changes may be clinically relevant. Therefore, the overarching goal of this ongoing initiative is to understand the changes in methylomic profiles occurring after aSAH to identify biomarkers predictive of prognosis and recovery outcomes. The purpose of this specific study was to develop and implement a pipeline for cleaning and quality-checking methylomic profiles derived from CSF tissue and to determine the suitability of peripheral blood as a surrogate for CSF.

MATERIALS AND METHODS

Study Design Overview

Our study population is comprised of individuals who have sustained an aSAH. Patient DNA was obtained from two biological tissues, CSF (drained as standard of care) and blood. This study investigated CSF samples collected longitudinally from 279 patients during the first 14 days of hospitalization, and blood samples from 88 of these individuals collected within the first day of hospitalization. Methylomic profiles were obtained using a genome-wide array, from which methylation levels, quantified as beta-values (i.e., percent methylation) and M-values (i.e., a transformation of the beta-values, which exhibit beneficial properties for statistical analysis), were assessed for over 450,000 cytosine-phosphate-guanine (CpG) sites. QC analyses of methylation data were performed in the R statistical computing environment using the following packages: minfi (Aryee et al., 2014), ENmix (Xu et al., 2016), and sva (Leek et al., 2012).

After QC, cleaned methylomic profiles were contrasted between blood and CSF samples to determine the utility of blood as surrogate for CSF.

Patient Recruitment and Sample Collection

Participants were considered for this study if they were admitted to the University of Pittsburgh Medical Center Neurovascular Intensive Care Unit with an aSAH confirmed by digital subtracted cerebral angiography and/or head computed tomography (CT) and a Fisher grade (measure of hemorrhage burden) $> 1$. Informed consent was obtained from the participant or their legal proxy using a protocol approved by the University of Pittsburgh Institutional Review Board. Exclusion criteria included a history of debilitating neurologic disease or subarachnoid hemorrhage due to arteriovenous malformation, trauma, or mycotic aneurysm.

Daily CSF samples were collected for the first 14 days after aSAH from an external ventricular drain placed as standard of care and DNA extracted using the Qiamp Midi kit (Qiagen, Valencia, CA, United States). Venous blood was collected within the first day of hospitalization and DNA was extracted using a simple salting out procedure. All DNA was stored in 1X TE buffer at 4°C.

This study included 279 aSAH patients. For the CSF samples, we targeted days 1, 4, 7, 10, and 13 post-aSAH, and substituted samples ±1 day when target days were unavailable. Blood samples collected within the first day of hospitalization after aSAH were included in this study for 88 of the 279 participants.

Potential Covariate Assessments

The severity of aSAH was assessed at hospital admission by Fisher grade (Fisher et al., 1980) employing CT scan to assess hemorrhage burden and by Hunt and Hess scores (Hunt and Hess, 1968) to assess symptom burden. Demographic and anthropometric characteristics such as age, sex, race, height, and weight were collected from medical records (Table 1). Smoking status was also collected.

DNA Methylation Data Collection and Plate Design

The Illumina (San Diego, CA, United States) HumanMethylation450 BeadChip platform was used to assess the methylation levels at over 450,000 CpG sites in the samples. Methylation data collection was performed by the Center for Inherited Disease Research (CIDR) of Johns Hopkins University. Each BeadChip, hereafter referred to as a plate,
than three standard deviations below the mean of all samples, CSF samples. Samples having bisulfite control intensities less than the ENmix (Xu et al., 2016) was employed to assess the quality of samples from the same patient were carefully assigned to available positions within a chip so that longitudinal changes in methylation were not confounded with row and column effects. Third, cases and controls for DCI were balanced within chips so that longitudinal changes in methylation were not obscured by chip and plate effects. Second, row and column positioning of samples from the same patient were carefully assigned to available positions within a chip so that longitudinal changes in methylation were not confounded with row and column effects. Third, cases and controls for DCI were balanced within chips using a checkerboard pattern so that DCI was not confounded with row, column, chip, or plate effects (see Supplementary Figure 1 for the plate map). To gauge technical variation, we included four control samples of fixed methylation state (0, 30, 70, and 100% methylated) and four technical replicates (i.e., repeated assays of the same DNA sample) per plate. Two of the control samples were placed in the same position across all plates and two were randomly placed. For the plate of blood samples, all four technical replicates were randomly positioned duplicates. In contrast, for the 11 plates of CSF samples, three of the four technical replicates were randomly chosen duplicate samples, and one was the same sample replicated across all 11 plates.

**Sample Quality Functional Normalization**

ENmix (Xu et al., 2016) was employed to assess the quality of samples in our methylation study, separately for blood and CSF samples. Samples having bisulfite control intensities less than three standard deviations below the mean of all samples, and/or for which more than 1% of probes were inadequately detected (i.e., detection p-values > 0.01 or with fewer than three beads) were categorized as low-quality samples. These, along with outliers in total intensity or beta value distribution were removed from our subsequent analyses (Xu et al., 2016). After the removal of low-quality and outlier samples, we performed background correction (Xu et al., 2016) to remove non-specific signals from the total signal, and performed dye bias correction (Xu et al., 2017). Sample quality differences by tissue type were tested using Fisher’s exact test on counts of samples passing or failing all sample QC filters.

We normalized the methylation data to bring Infinium Type I and Type II probes into alignment and to reduce noise and technical variation due to batch effects (i.e., plate, chip, row, and column effects). Specifically, we performed functional normalization, an extension of quantile normalization, which makes use of the control probes on the array to regress out unwanted variation in the methylation data (Fortin et al., 2014). Whether functional normalization improved agreement between technical replicates was tested by comparing the squared differences in median M-values between technical duplicates before and after normalization using a one-sided paired t-test.

**CpG Site-Level Quality Control**

After normalizing the data, we removed CpG sites from our analysis due to: (1) overlap of methylation probes with known polymorphic sites (which can cause biased methylation assessments), (2) probes located on the sex chromosomes (to rectify the artifacts arising due to unequal distribution of gender in the data) (Marabita et al., 2013), (3) cross-reactive probes that bind to alternate genomic sequences, (4) probes exhibiting multi-modal distributions indicative of poor quality or bias (Xu et al., 2016) and (5) probes that were inadequately detected (i.e., detection p-values > 0.01 or with fewer than three beads) in more than 1% of samples. Differences in the number of CpGs passing quality filters was tested using McNemar’s test.

**Reference Based Cell Proportions for Blood**

Blood has a mixture of cell types and DNA methylation-based references have been established for blood cells. Therefore, to estimate the proportions (cell counts) of each cell type, we employed Houseman’s reference based method (Houseman et al., 2012) using the functions available in the minfi R package (Aryee et al., 2014) in our blood data. The method is based on using DNA methylation as a surrogate measure for cell type distributions and outputs the proportion of cell types: CD4 + T cells, CD8 + T cells, natural killer cells, monocytes, B -cells and granulocytes in each sample. The proportion of all cell types equals to one for each sample.

**Cell-Type Heterogeneity Correction and Simulated EWAS Under the Null Hypothesis**

Owing to the lack of reference methylation data for cell types found in CSF after an aSAH event we employed surrogate...
variable analysis (SVA) to perform reference-free adjustment for
cell-type heterogeneity across the samples in blood and CSF data. SVA,
as implemented in the sva R package (Leek et al., 2012),
simultaneously models the effects of known sources of variation
covariates) and unknown sources of variation (i.e., surrogate
variables), conditional on a phenotype of interest. Including the
phenotype of interest in this modeling approach is necessary to
prevent the surrogate variables from accounting for variation due to,
for example, differences between cases and controls of disease,
so as not to stymie subsequent analyses aimed at detecting CpG
sites associated with case/control status. For examining the utility
of surrogate variables in adjusting for cell-type heterogeneity
in the absence of any particular phenotype-specific analyses,
we generated a random trait by randomly permuting one of
our observed traits, DCI, to serve as our outcome of interest.
SVA was performed for this simulated trait along with age and
gender as covariates in the context of an EWAS, whereby each
CpG was individually tested for association with the simulated
trait. Given the repeated measures in CSF, we grouped the CSF
samples into five subsets centered on their target days (days
1, 4, 7, 10, and 13) and substituted samples ±1 day when a
sample on the target day was unavailable. The goal of performing
SVA cross-sectionally in CSF subsets is to retain the variation in
methylation related to time. EWAS was also performed for the
simulated trait without adjusting for surrogate variables (with
other covariates being the same) and the distribution of \( p \)-values
for SVA-adjusted and unadjusted EWAS scans under the null
hypothesis were qualitatively compared to determine effect of
SVA on genomic inflation. We measured inflation/deflation using
the genomic inflation factor (\( \lambda \)), which is defined as the ratio of
the empirically observed to expected median of the distribution
of the test statistic.

**Comparisons of Blood and CSF Methylation Profiles**

We compared the methylation profiles of individuals with blood
samples collected within the first day after hospitalization and
CSF samples collected at days 1, 4, 7, 10, and 13. We used 65,
64, 65, 61, and 47 subjects to compare the methylation profiles
of blood and CSF at days 1, 4, 7, 10, and 13, respectively to facilitate
individual level comparison. For this comparison, following the
approach of Ma et al. (2014), we excluded CpG sites where all
of the individual beta values were above 90% or below 10%
across both blood and CSF, as methylation at these sites had
little variation across samples and therefore would show high
correlation due to this uninteresting reason. The \( M \)-values at
each qualifying CpG site were adjusted for age, sex and the
surrogate variables (generated so as to not retain variation due to
any particular confounder, as one might typically do when
analyzing a trait of interest), and were then used to calculate
correlation coefficients between the blood and CSF profile across
samples. In addition to these within-CpG correlations, we also
calculated within-individual blood-CSF correlation coefficients
across the methylome for each of the 70 patients who had data
for both tissue types, using the same adjusted \( M \)-values as above.
To mitigate the potential batch effect resulting from our design
that blood and CSF samples were assayed on separate plates, we
chose to compare blood and CSF by calculating their correlation
which is invariant to systematic shifts in mean and scale, rather
than by directly comparing their absolute \( M \)-values.

**RESULTS**

**Sample-Level Quality Control**

A total of 1,012 methylation profiles (including 44 technical
replicates) were measured from CSF samples collected
longitudinally from 279 aSAH patients. Additionally, 92
methylation profiles (including 4 technical replicates) were
measured on blood samples in a subset of 88 of these patients; the
majority of these blood samples (77) were sampled between zero
and 2 days post-hospitalization (Supplementary Table 1). QC
analyses and filtering procedures were performed separately for
CSF and blood samples. Based on low average bisulfite intensity
and/or high proportion of poorly detected probes, we identified
89 (of 1012; 8.8%) poorly performing CSF samples (Figure 1).
Additionally, we identified 3 (0.3%) more CSF outliers based on
low total intensity. In contrast, no blood samples (0 of 92; 0%)
failed these criteria. Figure 2 displays the beta-value distributions
of all samples collected, based on which one blood and one
additional CSF samples were identified as outliers. In total, poor
sample performance was more common for CSF (93 of 1,012,
9.1%) than for blood (1 of 92, 1.1%), and these differences in
quality of methylation profiling by tissue type were statistically
significant (Fisher's exact test \( p = 0.003 \)). Supplementary Table 1
gives counts of all samples collected and samples retained after
QC, for each collection time day.

After removing low-quality samples, we performed functional
normalization to reduce probe type (Infinium Type I vs. Type
II) and batch (i.e., plate, chip, row, and column) effects. The
reduction in chip, row, and column effects can be visualized in
the distribution of \( M \)-values, before and after functional
normalization, for samples profiled together on a plate (Figure 3).
Row effects are apparent for some chips as increasing means
across adjacent samples. For example, before normalization the
third chip from the left in Figure 3A shows strong row effects
indicated by means forming an upwardly sloped trend across the
first to fifth samples (which correspond to ascending rows in the
first column), followed by another upwardly sloped trend across
the sixth to eleventh samples (which correspond to ascending
rows in the second column). Functional normalization increased
concordance in median methylation between 34 technical
replicate CSF samples (\( p = 0.015 \)) (Figure 4). For the 4 technical
replicate blood samples, the same trend of increased concordance
after functional normalization was observed; however, this trend
was not statistically significant (\( p = 0.153 \)).

**CpG Probe-Level Quality Control**

Individual probes were filtered out of analyses for reasons
pertaining to probe design such as overlap with any single
nucleotide polymorphisms (SNPs) and with cross-reactivity
with off-target genomic positions (using the minfi R package,
FIGURE 1 | Identification of low-quality samples (red) based on high proportion of poorly detected probes (x-axis) and/or low average bisulfite intensity (y-axis) from (A) 92 blood samples and (B) 1,012 CSF samples, both including technical replicates. The horizontal lines represent the threshold 3 SD below the mean across samples for bisulfite intensity, and the vertical lines represent the threshold of 1% of probes for which detection was poor (based on detection p-value and number of beads).

FIGURE 2 | Distribution of beta-values across (A) all blood and (B) all CSF samples shows that a subset of poorly performing samples (red) deviate from the typical distribution. After removal of poor performing samples, distributions in (C) blood and (D) CSF are more consistent.
Aryee et al., 2014). Additionally, CpG probes on the sex chromosomes were excluded. Based on QC analyses, CpG probes with multimodal beta-value distributions, low detection quality across samples, and high technical variation across replicate samples were also filtered out of analyses. CpG probe-level filtering criteria are summarized in Table 2. For each QC filtering step, and overall, fewer CpGs were filtered out in blood than in CSF ($p < 2.2 \times 10^{-16}$ for all), indicating that CSF samples may yield somewhat lower-quality methylation data, as is also evident in Figure 1.

### B-cell Leukemia Outlier

Estimated blood cell type proportions using the reference-based method followed expectations for all blood samples with one exception, which showed high B-cell composition in analysis. Further clinical investigation confirmed the presence of chronic lymphocytic leukemia (CLL) in the individual, which is known to cause increased proliferation of B cells in blood, bone marrow and other lymphoid tissues (Greenberg and Probst, 2013; Ciccone et al., 2014; Ghia and Hallek, 2014; Zhang and Kipps, 2014; Hallek, 2015). Samples from this participant were excluded from further analyses.

### Adjustment for Cell Type Heterogeneity

Because methylic profiles differ widely by cell type, modeling cell type heterogeneity across samples is crucial for valid cross-sample analyses of methylation data. However, external cell type-specific reference data was not available for post-aSAH CSF for use in reference-based adjustment. Therefore, we performed reference-free adjustment using SVA to remove unknown sources of variation including cell type heterogeneity. We further excluded technical replicates from all samples that passed QC, leaving 70 blood samples and 154, 246, 217, 152, and 95 CSF samples for days 1, 4, 7, 10, and 13, respectively. Ten surrogate variables (SVs) were generated for the set of blood samples, and 13 SVs were generated for day 1 CSF samples. Fifteen, 15, 14 and 10 surrogate variables were generated for CSF samples for days 4, 7, 10, and 13 respectively. To determine the benefit of SV-adjustment, we interrogated its effect on CpG site association tests under the null model of no association by simulating a dummy binary phenotype similar to the distribution of DCI and performing EWAS, with and without including SVs as covariates. The behavior of the test statistic better followed the null distribution after SV-adjustment, as shown in quantile-quantile plots (Figure 5). Specifically, genomic inflation factor ($\lambda$) improved from 1.11 to 0.98 in the set of blood samples, and improved from 0.73 to 0.99 in the set of CSF samples within 2 days after hemorrhage (Figure 5) and likewise in other CSF subsets (Supplementary Figures 2, 3). Genomic deflation may be caused by sources of variation including cell type heterogeneity that cause correlation across CpG sites within a sample, equating to a reduction in the effective number of independent tests. These results show that in the absence of reference data, SVA aids in controlling the adverse impact of

![Figure 3](image-url) Functional normalization reduces batch effects. Boxplots show the distribution of $M$-values per sample across the plate of (A) blood samples before, and (B) after, functional normalization. For each sample, the median $M$-value is indicated by the black horizontal line and the interquartile range (25th to 75% percentile) is indicated by the colored box. The whiskers (dashed lines) extend to the most extreme data point within 1.5 times the interquartile range beyond the box, and outlier points beyond this limit are shown individually as circles. Samples are color coded by chip, and samples are ordered within each chip as follows: first column ascending by row number followed by second column ascending by row number. Before normalization, chip effects are apparent as differences in median and interquartile range between color groups. (C) CSF samples before, and (D) after, functional normalization on an example plate. Comparing the blow-ups to the right of each plot show variation in median $M$-values across samples is reduced after functional normalization.
cell-type heterogeneity and other sources of unwanted variation on tests of epigenetic association.

**Correlation Was Low When Comparing DNA Methylation of Post-aSAH Blood and CSF**

Following our long-term goal of understanding the methylic changes occurring across tissues after aSAH, we explored the suitability of peripheral blood collected within the first day of hospitalization as a surrogate for the normally less accessible longitudinally collected CSF based on the within-CpG correlation of adjusted $M$-values between the two tissue types obtained from aSAH patients. Specifically, we compared the methylation profile of blood collected within 48h of hospitalization versus CSF samples collected at days 1, 4, 7, 10, and 13 post rupture, respectively. Table 3 summarizes the numbers of CpGs used and the correlation coefficients for each day. In general, the mean within-CpG correlation ($0.23–0.26$) was too low to use blood as a surrogate for post-aSAH CSF in a global manner.

Differences were observed in the magnitude of the correlation by genomic position (CpG island, shore, shelf, and open sea; $p < 0.001$ for all), with islands and shores showing greater positive correlation than shelves and seas (Figure 6 and Supplementary Figures 4–7). Similarly, the magnitude of the correlation differed by the orientation of CpG with respect to the nearest gene [(3′ UTR, TSS, Exon, Body, 5′UTR), $p < 0.01$], with CpG sites near the transcription start site or first exon showing greater inter-tissue correlation than CpG sites in the upstream, downstream or in the body of genes. The CpGs sites upstream or in the body of genes, in turn, showed greater correlation than CpG sites downstream of the gene.

In addition to the within-CpG correlations, we also examined how correlated the blood and CSF methylation profiles were within each individual patient. The mean within-individual correlation coefficients for five time points of CSF collection range from 0.946 to 0.960, with little variability among individuals (Supplementary Figure 8), indicating an overall strong between-tissue correlation within individuals. As time post aneurysmal rupture progresses, the correlation

---

**TABLE 2 | CpG probe-level filters.**

| Sequential filtering step                           | Blood* | CSF*  |
|-----------------------------------------------------|--------|-------|
|                                                     | Filtered | Retained | Filtered | Retained |
| None                                                | 485,512 |         | 485,512|
| Probe sequence overlapping SNP                      | 17,541 | 467,971 | 17,541 | 467,971 |
| Off-target cross-reactivity                         | 36,489 | 431,482 | 36,489 | 431,482 |
| Sex chromosome                                      | 10,191 | 421,291 | 10,191 | 421,291 |
| Multimodal beta-value distribution                 | 2,072  | 419,219 | 6,142  | 415,149 |
| Low-quality detection                               | 972    | 418,247 | 1,300  | 413,849 |

*McNemar p-value ($< 2.26 \times 10^{10}$) across all five filtering steps combined.
between blood (collected at a single early timepoint) and CSF (collected longitudinally) first increases, and then decreases after reaching its peak at day 7, which likely reflects the changing pathophysiological response to the rupture event over time.

**DISCUSSION**

Our protocol demonstrated the value of several QC procedures in obtaining clean and useful methylation data for subsequent scientific analyses. In particular, in addition to quality filters at the sample and CpG probe level, we showed that functional normalization was helpful in reducing batch effects for both blood and CSF. Likewise, SVA was useful for adjusting for unknown sources of variation, including cell type heterogeneity, as evidenced by improved genomic inflation factor for a simulated EWAS scan under the null hypothesis. This observation is particularly important for studies of tissue types, such as CSF, that are underrepresented in the methylomics literature, and for which external cell type reference data are not yet available. We also provided evidence that, overall, CSF samples yielded lower-quality methylomic data than didblood samples. This observation may reflect the low cell content (Svenningsson et al., 1995; de Graaf et al., 2011a,b) in CSF compared to blood. Altogether, these lessons can inform the design of future analyses seeking to investigate the methylomic profiles in post-aSAH CSF samples. The efficiency of a reference-based method in capturing the outlier with high proportion of B-cells is promising.

Epigenetic profiles are known to be different across tissues and cell types, though, the degree to which has not yet been assessed for blood and CSF using a whole methylome approach. We explored the question of whether methylomic profiles from blood samples could serve as surrogates for less accessible CSF. The generally low within-CpG correlations observed were consistent

---

**TABLE 3** Correlation analysis of blood (within first day of hospitalization) and CSF at different times.

| Days of CSF samples | Day 1 | Days 4 | Days 7 | Days 10 | Days 13 |
|---------------------|-------|--------|--------|---------|--------|
| No. of subjects     | 65    | 64     | 65     | 61      | 47     |
| CpG sites           | 266,009 | 257,979 | 255,624 | 256,758 | 255,459 |
| Mean correlation value | 0.233 | 0.263 | 0.262 | 0.253 | 0.242 |
| Median correlation value | 0.174 | 0.199 | 0.197 | 0.190 | 0.187 |
with an expectation based on tissue differences, indicating that blood cannot serve as a useful surrogate for CSF for most scientific or clinical purposes. When broken down by genomic annotations, regulatory regions such as CpG islands and locations near transcriptional start sites of genes showed significant positive correlations. To understand the methylomic changes that occur post-aSAH, we believe that CSF would be a most relevant source, representing the central nervous system (CNS) environment and its proximity to the hemorrhagic location. We note that the overall low within-CpG correlation is not at odds with the observed strong within-individual correlation. The within-CpG correlation is more pertinent to downstream analysis where the methylation level at individual CpGs are compared between groups (for example, cases and controls). One possible limitation of our correlation analysis is that blood and CSF samples were measured on different plates. However, correlation coefficients have the property of being invariant with linear changes and therefore our results are not likely to be confounded by the blood-CSF plate batch effect.

This study benefited from several strengths including the plate design aimed at reducing confounding of experimental effects with technical artifacts within each tissue, thorough and rigorous application of data QC procedures, pairing of blood and CSF samples from the same patients, and assessment of methylomic profiles in a novel tissue type (post-aSAH CSF) that captures the CNS environment post-aSAH. Despite these strengths, limitations of the current study include limited statistical power to resolve the intra subject differences among the samples that may ultimately pose challenges in using this dataset for future EWAS studies. Additionally, the cell composition of CSF may vary over time after hemorrhage, which would also affect the methylation levels. Thus, longitudinal analyses of post-aSAH samples are challenging as cell-type heterogeneity may be confounded with days post-injury. Overcoming these challenges will be necessary to accomplish goals such as identifying genes whose changes in methylation after injury are predictive of recovery outcomes.

In conclusion, this study is one of the first attempts to investigate DNA methylation at the genome scale in a sample of aSAH patients, as well as one of the first to measure methylation in CSF. Our analysis protocol showed that methylomic profiles can be obtained from CSF for use in EWAS analysis and that QC steps can improve the analysis by eliminating low-quality data points and reducing biases and experimental artifacts. Likewise, we show that blood, while readily accessible, is not a sufficient surrogate for the methylomic status of CSF. Our study lays the groundwork for more comprehensive analyses in the future, where efforts to understand methylation profiles in aSAH patients, and changes that occur post-injury, may ultimately lead to the discovery of biomarkers of clinical utility in predicting patient recovery.

DATA AVAILABILITY STATEMENT
The data can be accessed through dbGAP: phs001990.v1.p1.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by University of Pittsburgh Institutional Review Board. The patients or participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS
YC was the principal investigator of the project. YC, DW, and JS conceived and designed the study. AA, DL, TK, JS,
and DW performed the experiments and statistical analysis. AA, JS, and DW contributed to the initial writing of the manuscript. EC contributed to the clinical investigation of the research. All authors reviewed, edited, and approved the final manuscript.

FUNDING

Funding for this study was provided by the National Institute of Health (R01NR013610, R01CA221882, and R01NR004339).

ACKNOWLEDGMENTS

Foremost, we thank the participants of this study for making this work possible. We thank UPMC for access of the clinical samples.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.00671/full#supplementary-material

REFERENCES

Aryee, M. J., Jaffe, A. E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A. P., Hansen, K. D., et al. (2014). Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363–1369. doi: 10.1093/bioinformatics/btu049

Ciccone, M., Ferrajoli, A., Keating, M. J., and Calin, G. A. (2014). SnapShot: chronic lymphocytic leukemia. Cancer Cell 26, 770–781.

de Graaf, M. T., de Jongste, A. H., Kraan, J., Boonstra, J. G., Sillevis Smitt, P. A., and Gratama, J. W. (2011a). Flow cytometric characterization of cerebrospinal fluid cells. Cytometry B Clin. Cytom. 80, 271–281. doi: 10.1002/cyto.b.20605

de Graaf, M. T., Smitt, P. A., Luitwieler, R. L., van Velzen, C., van den Broek, P. D., Kraan, J., et al. (2011b). Central memory CD4+ T cells dominate the normal cerebrospinal fluid. Cytometry B Clin. Cytom. 80, 43–50. doi: 10.1002/cyto.b.20542

Endres, M., Meisel, A., Binisziewicz, D., Namura, S., Prass, K., Ruscher, K., et al. (2000). DNA methyltransferase contributes to delayed ischemic brain injury. J. Neurosci. 20, 3175–3181. doi: 10.1523/neo.20-09-03175.2000

Fisher, C. M., Kistler, J. P., and Davis, J. M. (1980). Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 6, 1–9. doi: 10.1227/00006123-198001000-00001

Fortin, J. P., Labbe, A., Lemire, M., Zanke, B. W., Hudson, T. J., Fertig, E. J., et al. (2014). Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol. 15:503.

Ghia, P., and Hallek, M. (2014). Management of chronic lymphocytic leukemia. Haematologica 99, 965–972.

Greenberg, E. M., and Probst, A. (2013). Chronic leukemia. Crit. Care Nurs. Clin. North Am. 25, 459–470.

Hallek, M. (2015). Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 90, 446–460. doi: 10.1002/ajh.23979

Houseman, E. A., Accomando, W. P., Koestler, D. C., Christensen, B. C., Marsit, C. J., Nelson, H. H., et al. (2012). DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 13:86. doi: 10.1186/1471-2105-13-86

Hunt, W. E., and Hess, R. M. (1968). Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J. Neurosurg. 28, 14–20. doi: 10.3171/jns.1968.28.1.0014

Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., and Storey, J. D. (2012). The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882–883. doi: 10.1093/bioinformatics/bts034

Ma, B., Wilker, E. H., Willis-Owen, S. A., Byun, H. M., Wong, K. C., Motta, V., et al. (2014). Predicting DNA methylation level across human tissues. Nucleic Acids Res. 42, 3515–3528. doi: 10.1093/nar/gkt1380

Marabita, F., Almgren, M., Lindholm, M. E., Ruhmann, S., Fagerstrom-Billai, F., Jagodic, M., et al. (2013). An evaluation of analysis pipelines for DNA methylation profiling using the Illumina HumanMethylation450 BeadChip platform. Epigenetics 8, 333–346. doi: 10.4161/epi.24008

Morris, T. J., and Beck, S. (2015). Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data. Methods 72, 3–8. doi: 10.1016/j.ymeth.2014.08.011

Nelson, E. D., Kavalali, E. T., and Monteglia, L. M. (2008). Activity-dependent suppression of miniature neurotransmission through the regulation of DNA methylation. J. Neurosci. 28, 395–406. doi: 10.1523/neo.3796-07.2008

Stapel, M., Piper, C., Yang, T., Li, M., Stowell, C., Xiong, Z. G., et al. (2010). Polycomb group proteins as epigenetic mediators of neuroprotection in ischemic tolerance. Sci. Signal. 3:ra15. doi: 10.1126/scisignal.2000502

Svenningsson, A., Andersen, O., Edsbergg, M., and Stemme, S. (1995). Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid. J. Neuroimmunol. 63, 39–46. doi: 10.1016/0165-5728(95)00126-3

Wermers, M. J., Kool, H., Albrecht, K. W., Rinkel, G. J., and Group Aneurysm Screening after Treatment for Ruptured Aneurysms Study. (2007). Subarachnoid hemorrhage treated with clipping: long-term effects on employment, relationships, personality, and mood. Neurosurgery 60, 91–97.

Xu, Z., Langie, S. A., De Boever, P., Taylor, J. A., and Niu, L. (2010). RELIC: a novel dye-bias correction method for Illumina Methylation BeadChip. BMC Genomics 11:84. doi: 10.1186/1471-2164-11-342-3

Zhang, S., and Kipps, T. J. (2014). The pathogenesis of chronic lymphocytic leukemia. Annu. Rev. Pathol. 9, 103–118.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Arockiaraj, Liu, Shaffer, Koleck, Crago, Weeks and Conley. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.